NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01108458 2017-03-03A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic AdenocarcinomaStanford UniversityPhase 2 Terminated1 enrolled 4 charts